Hypertension: Anti-hypertension drugs and COVID-19 risk

The initial hypothesis was that the use of renin-angiosin-aldosterone system inhibitors was positively associated with the risk of neocoopne pneumonia (COVID-19), but recent evidence suggests a negative correlation between the two.
, researchers looked at whether the risk of COVID-19 in patients treated with angiotensin-converting enzyme inhibitors (ACE) and angiotensin-blockers (ARBs) varied depending on the type of antihypertensive drug compared to calcium channel blockers (CCBs), according to a recent study published in hyperthermal journal Hypertension.
between 15 February 2020 and 7 June 2020, the researchers followed three queues in the French NHS database, ACE inhibitors, ARB and CCCB users, aged between 18 and 80.
researchers excluded patients with a history of diabetes, cardiovascular disease, chronic kidney failure or chronic respiratory disease from the past five years, and considered only patients with high blood pressure without complications.
the main endpoint of the study was COVID-19 hospital stay.
end point is the intring/death time during hospitalization due to COVID-19.
in the population of nearly 2 million people with hypertension (ACE inhibitors: 566023; ARB: 958227; CCB: 358306), follow-up 16 weeks, 2338 hospitalizations, 526 deaths or intages due to COVID-19.
ACE inhibitors and ARB users had a lower risk of hospitalization (risk ratio of 0.74 (95% CI 0.65-0.83) and 0.84 (0.76-0.93) and lower risk of intage/death, respectively, compared to CCBs users.
risk of using ACE inhibitors was slightly lower than in patients using ARB.
large observational study may indicate a lower risk of COVID-19 in patients with high blood pressure treated with ACE inhibitors or ARBs over a long period of time than CCBs.